Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

BioLineRx (BLRX) EBITDA: 2023-2025

Historic EBITDA for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $3.9 million.

  • BioLineRx's EBITDA rose 714.05% to $3.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$746,000, marking a year-over-year increase of 97.60%. This contributed to the annual value of -$20.4 million for FY2024, which is 58.93% up from last year.
  • Per BioLineRx's latest filing, its EBITDA stood at $3.9 million for Q2 2025, which was down 23.15% from $5.1 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's EBITDA peaked at $18.5 million during Q2 2023, and registered a low of -$18.6 million during Q4 2023.
  • For the 3-year period, BioLineRx's EBITDA averaged around -$2.5 million, with its median value being -$2.6 million (2024).
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 97.39% in 2024, then soared by 836.64% in 2025.
  • Quarterly analysis of 3 years shows BioLineRx's EBITDA stood at -$18.6 million in 2023, then soared by 76.16% to -$4.4 million in 2024, then surged by 714.05% to $3.9 million in 2025.
  • Its EBITDA was $3.9 million in Q2 2025, compared to $5.1 million in Q1 2025 and -$4.4 million in Q4 2024.